Abstract: The present invention relates to sulfonamide compounds Formula (I) wherein the substituents are as described herein and their use in a medicine for the treatment of diseases disorders associated with the inhibition of Voltage gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof pharmaceutical compositions thereof useful in treating diseases disorders syndromes and/or conditions associated with the inhibition of Voltage gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention. (I)
| # | Name | Date |
|---|---|---|
| 1 | 201827006962-STATEMENT OF UNDERTAKING (FORM 3) [23-02-2018(online)].pdf | 2018-02-23 |
| 2 | 201827006962-PRIORITY DOCUMENTS [23-02-2018(online)].pdf | 2018-02-23 |
| 3 | 201827006962-POWER OF AUTHORITY [23-02-2018(online)].pdf | 2018-02-23 |
| 4 | 201827006962-FORM 1 [23-02-2018(online)].pdf | 2018-02-23 |
| 5 | 201827006962-DECLARATION OF INVENTORSHIP (FORM 5) [23-02-2018(online)].pdf | 2018-02-23 |
| 6 | 201827006962-COMPLETE SPECIFICATION [23-02-2018(online)].pdf | 2018-02-23 |
| 7 | 201827006962-FORM 3 [07-04-2018(online)].pdf | 2018-04-07 |
| 8 | 201827006962-Proof of Right (MANDATORY) [17-04-2018(online)].pdf | 2018-04-17 |
| 9 | 201827006962.pdf | 2018-08-11 |
| 10 | 201827006962- ORIGINAL UR 6( 1A) FORM 1-250418.pdf | 2018-08-11 |
| 11 | 201827006962-FORM 3 [17-11-2018(online)].pdf | 2018-11-17 |
| 12 | 201827006962-FORM 3 [23-01-2019(online)].pdf | 2019-01-23 |
| 13 | 201827006962-FORM 3 [30-01-2019(online)].pdf | 2019-01-30 |
| 14 | 201827006962-FORM 3 [07-05-2019(online)].pdf | 2019-05-07 |